Forbion

Join us in congratulating Professor Alberto Auricchio, founder and Chief Scientific Officer (CSO) of Forbion portfolio company AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, on his appointment as President and Board member of the European Society of Gene and Cell Therapy (ESGCT). The ESGCT Board is composed of researchers and clinicians representing a broad range of European Countries. Members are elected by nomination and vote at the Annual General Meeting. Election to the Board of ESGCT recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. Click on the following link to read more: https://lnkd.in/ecNXyxYe #appointment #lifesciences #venturecapital #biotech #news #portfolio #portfoliocompany Dr. Dmitrij Hristodorov Tim Lohoff, Ph.D.

Exciting news that our portfolio company Noema Pharma, a clinical-stage neuroscience-based biotech, has achieved significant progress in its mission to treat debilitating central nervous system (CNS) disorders. Today, Noema announced that the Phase 2a ALLEVIA-1 study with NOE-105 (gemlapodect) in patients with Tourette syndrome successfully met its primary and all key secondary endpoints. This achievement marks an important step forward for patients affected by Tourette syndrome and highlights the potential of innovative approaches in neuroscience. Congratulations to the entire Noema Pharma team. We are excited to continue supporting your journey to transform the landscape of CNS treatment. Click on the following link to learn more: https://lnkd.in/ebYmHaYX #Forbion #NoemaPharma #Neuroscience #TouretteSyndrome #CNS #Biotech #Innovation #LifeSciences #Biotech Nanna Lüneborg Audrey Cacaly

An exciting day for us today as we host our investors for our Annual Investor Meeting in Amsterdam. This year we were immensely proud to launch our newest effort: The Forbion EU Impact Roundtable to our LPs. In this inaugural session we focused on "Empowering Women's Health in 2024." In a gathering that got together diverse leaders from pharma, venture capital, academia and NGOs, the panel discussed the state of research in women's health and how to pave a way forward. A huge thank you to our panelists Mary Kerr, CEO of NeRRe Therapeutics Ltd, Kelle Moley, Global VP of Clinical & Translational R&D, Reproductive Medicine & Maternal Health at Ferring Pharmaceuticals, Diana Torgersen Head of Innovation Ecosystem Integration at Organon and Trine Bartholdy, Chief Business Officer at BioInnovation Institute. We are grateful for their insights and commitment to advancing women's health. Stay tuned for the full session recording. #Forbion #ImpactRoundtable #WomensHealth #VentureCapital #Pharma #InvestingInImpact #biotech

Forbion Raises Over €2 Billion Across Two New Funds, Bringing Total Assets Under Management to €5 Billion   We are thrilled to announce our largest fundraising to date, securing over €2 billion ($2.2 billion) for two new funds. Forbion Growth Opportunities Fund III closed at €1.2 billion ($1.3 billion), and Forbion Ventures Fund VII raised €890 million ($980 million), bringing our total assets under management to €5 billion ($5.5 billion). This significant fundraising follows a period of outstanding performance, with six recent exits valued at over $1 billion each. Forbion’s continued growth reflects our commitment to supporting and building life sciences companies that drive impactful change across the healthcare landscape. We look forward to leveraging this new capital to continue our mission of impacting the future of medicine. We are grateful for the trust and support from our investors as we work to accelerate innovation in the life sciences sector. Click on the following link to learn more: https://lnkd.in/eUrYVC2k #Forbion #LifeSciences #VentureCapital #Fundraising #HealthcareInnovation #Biotech #GrowthOpportunities #InvestingInInnovation 

Forbion is pleased to announce a new chapter for our portfolio company, Calluna Pharma. The company welcomes Mark Altmeyer as the incoming Chairman and Mark Gaffney as its incoming CEO. We would also like to thank John Montana for his leadership and dedication in building a strong foundation at Calluna Pharma. John will return to his role as an Operating Partner at Forbion. Click on the following link to learn more: https://lnkd.in/ezn5RaZF #biotech #pharma #forbion #portfolio #leadership #lifesciences #biotech

Forbion Proudly Backs Purespring Therapeutics in Series B Financing. Purespring Therapeutics has raised £80 million ($105 million) in an oversubscribed Series B financing round. The round was led by Sofinnova Partners, with collaboration from Gilde Healthcare, Forbion, British Patient Capital, and founding investor Syncona Limited . The funds will accelerate the advancement of Purespring’s AAV pipeline of gene therapy programs, which are set to revolutionize the treatment of kidney diseases. This includes the development of their lead program targeting IgA Nephropathy (IgAN), a serious kidney condition with unmet medical needs. We are excited to support Purespring in their journey to transform the field of gene therapy for kidney disease. #Lifesciences #biotech #kidneydiseases #SeriesB #financing Click the following link to learn more: https://lnkd.in/eYqDnrz3 Marco Boorsma Tim Lohoff, Ph.D. Gilles van Tienderen, PhD

We are thrilled to share that Mestag Therapeutics, a Forbion portfolio company, has entered into a license and research collaboration with MSD, a global leader in healthcare. This partnership leverages Mestag’s proprietary Reversing Activated Fibroblast Technology (RAFT) platform to identify new targets in the fight against inflammatory diseases. Through this collaboration, Mestag will deploy RAFT to interrogate the pathogenic role of fibroblasts, uncovering novel insights and drug targets. MSD will have the option to license these targets, aiming to drive forward the discovery, development, and commercialization of breakthrough therapeutics. Congratulations to the Mestag team on this significant milestone. We look forward to seeing the transformative potential this collaboration brings to the treatment of inflammatory diseases. Click on the following link to read the official company release: https://lnkd.in/eURDhksN Antoine Boulanger #lifesciences #biotech

Forbion portfolio company AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces three oral presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting (ESGCT), to be held October 22-25 in Rome. To view the oral presentation details click on the following link: https://lnkd.in/e83VgRC2 #lifesciences #biotech #portfoliocompany #news #cellandgenetherapy Dr. Dmitrij Hristodorov Tim Lohoff, Ph.D.

Forbion is proud to announce the successful close of a £35 million Series A financing in LoQus23 Therapeutics Ltd, a pioneering biotech company developing small molecule drugs aimed at tackling DNA instability and slowing neurodegeneration in Huntington’s Disease, myotonic dystrophy type 1, and other triplet repeat expansion diseases. This financing round, led by Forbion, brings together key investors, including SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion’s General Partner, Rogier Rooswinkel, will join the Board of Directors at LoQus23, marking an exciting step in advancing therapies for neurodegenerative diseases. #lifesciences #Biotech #smallmolecules #seriesA #Financing #Neurodegeneration Rogier Rooswinkel Gilles van Tienderen, PhD Click the following link to read more: https://lnkd.in/efUVKTZw

We are thrilled to announce that Melanie de Almeida, PhD and Gilles van Tienderen, PhD will step into new roles as Associates. Since joining Forbion, Melanie and Gilles have been instrumental in supporting critical deals and have consistently demonstrated their analytical strengths and dedication to our investment approach. We are proud to see their growth and look forward to their continued contributions in their new roles. Please join us in congratulating Melanie and Gilles on their well-deserved promotions! #Forbion #LifeSciences #VentureCapital #TeamGrowth #Biotech #Promotions #InvestmentLeadership